Evidence map›Paper›PMID 31806013›Full record

ArticleActa neuropathologica communications2019

Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.

Ruslan Al-Ali, Katharina Bauer, Jong-Whi Park, Ruba Al Abdulla, Valentina Fermi, Andreas von Deimling, Christel Herold-Mende, Jan-Philipp Mallm, Carl Herrmann, Wolfgang Wick and 1 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Chromatin accessibility profiling methods.Nature reviews. Methods primers · 2021
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ruslan Al-AliNeurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 460, 69120, Heidelberg, Germany.
Katharina BauerSingle-cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jong-Whi ParkNeurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 460, 69120, Heidelberg, Germany.
Ruba Al AbdullaInstitute of Research, Development and Innovation in Healthcare Biotechnology in Elche- IDiBE, Elche, Spain.
Valentina FermiDivision of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, INF 400, D-69120, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, University of Heidelberg, INF 224, D-69120, Heidelberg, Germany.
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, INF 400, D-69120, Heidelberg, Germany.
Jan-Philipp MallmSingle-cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Carl HerrmannHealth Data Science Unit, Medical Faculty University Heidelberg and BioQuant, 69120, Heidelberg, Germany.
Wolfgang WickNeurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 460, 69120, Heidelberg, Germany.
Şevin TurcanNeurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 460, 69120, Heidelberg, Germany. sevin.turcan@med.uni-heidelberg.de.ORCID 0000-0002-0885-5607
Heidelberg University · DEGerman Cancer Research Center · DECentre National de la Recherche Scientifique · FR

Funding

Deutsche Forschungsgemeinschaft FOR2647Deutsche Krebshilfe Max-Eder Program
6 · The paper itself

Abstract

The presence of genome-wide DNA hypermethylation is a hallmark of lower grade gliomas (LGG) with isocitrate dehydrogenase (IDH) mutations. Further molecular classification of IDH mutant gliomas is defined by the presence (IDHmut-codel) or absence (IDHmut-noncodel) of hemizygous codeletion of chromosome arms 1p and 19q. Despite the DNA hypermethylation seen in bulk tumors, intra-tumoral heterogeneity at the epigenetic level has not been thoroughly analyzed. To address this question, we performed the first epigenetic profiling of single cells in a cohort of 5 gliomas with IDH1 mutation using single nucleus Assay for Transposase-Accessible Chromatin with high-throughput sequencing (snATAC-seq). Using the Fluidigm HT IFC microfluidics platform, we generated chromatin accessibility maps from 336 individual nuclei, and identified variable promoter accessibility of non-coding RNAs in LGGs. Interestingly, local chromatin structures of several non-coding RNAs are significant factors that contribute to heterogeneity, and show increased promoter accessibility in IDHmut-noncodel samples. As an example for clinical significance of this result, we identify CYTOR as a poor prognosis factor in gliomas with IDH mutation. Open chromatin assay points to differential accessibility of non-coding RNAs as an important source of epigenetic heterogeneity within individual tumors and between molecular subgroups. Rare populations of nuclei that resemble either IDH mutant molecular group co-exist within IDHmut-noncodel and IDHmut-codel groups, and along with non-coding RNAs may be an important issue to consider for future studies, as they may help guide predict treatment response and relapse.A web-based explorer for the data is available at shiny.turcanlab.org.

Indexed as

Brain NeoplasmsCell NucleusChromatinCohort StudiesEpigenesis, GeneticGliomaHumansIsocitrate DehydrogenaseMutationSequence Analysis, RNAChromatinIDH1 protein, humanIsocitrate Dehydrogenase

Identifiers

PMID31806013
PMCPMC6896263
OpenAlexW2993922439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.